Protara Therapeutics, Inc. (TARA)
| Market Cap | 225.74M +81.1% |
| Revenue (ttm) | n/a |
| Net Income | -70.02M |
| EPS | -1.35 |
| Shares Out | 59.10M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 399,077 |
| Open | 3.990 |
| Previous Close | 3.990 |
| Day's Range | 3.785 - 3.990 |
| 52-Week Range | 3.020 - 7.820 |
| Beta | 1.49 |
| Analysts | Strong Buy |
| Price Target | 25.71 (+571.28%) |
| Earnings Date | Aug 11, 2026 |
About TARA
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company’s lead program is TARA-002, an investigational cell therapy, which is in phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headqu... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for TARA stock is "Strong Buy." The 12-month stock price target is $25.71, which is an increase of 571.28% from the latest price.
News
Protara Therapeutics reports Q2 EPS (36c), consensus (31c)
“In the second quarter, we strengthened our late-stage pipeline through continued operational execution, positioning us for multiple important milestones over the coming quarters,” said Jesse Shefferm...
Protara Therapeutics Earnings release: Q2 2026
Protara Therapeutics released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Protara Therapeutics Quarterly report: Q2 2026
Protara Therapeutics has published its Q2 2026 quarterly earnings report on August 11, 2026.
Protara Therapeutics Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
TARA-002 is advancing in both LM and NMIBC, with strong interim efficacy, streamlined FDA review, and pivotal trial milestones expected in H2. The therapy shows high response rates, favorable safety, and broad market potential, with pricing to reflect its differentiated value.
Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer...
Protara Therapeutics price target raised to $28 from $25 at Oppenheimer
Oppenheimer raised the firm’s price target on Protara Therapeutics (TARA) to $28 from $25 and keeps an Outperform rating on the shares. TARA-002’s opportunity in lymphatic malformations looks increasi...
Protara Therapeutics Transcript: KOL event
TARA-002 demonstrated high efficacy, safety, and durability in treating macrocystic and mixed lymphatic malformations, addressing a major unmet need. With strong interim results, favorable regulatory feedback, and a large market opportunity, TARA-002 is positioned for BLA submission in 2H 2027.
Protara Therapeutics Slides: KOL event
Protara Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 19, 2026.
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
Event will provide an overview of Lymphatic Malformations, the treatment landscape and the TARA-002 clinical program NEW YORK, May 18, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA...
Protara announces updated 12-month data from Cohort A of ADVANCED-2 trial
Protara Therapeutics (TARA) announced updated 12-month data from Cohort A of the ongoing Phase 2 open-label ADVANCED-2 trial of TARA-002 in patients with carcinoma in situ or CIS non-muscle invasive…
Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
TARA-002 demonstrates 72% complete response rate at any time, 67% complete response rate at the 6-month landmark and 55% complete response rate at the 12-month landmark in BCG-Naïve patients
Protara Therapeutics price target lowered to $26 from $27 at JPMorgan
JPMorgan lowered the firm’s price target on Protara Therapeutics (TARA) to $26 from $27 and keeps an Overweight rating on the shares.
Protara Therapeutics Registration statement: Registration filing
Protara Therapeutics filed a registration statement on May 14, 2026, providing details about a securities offering with the SEC.
Protara Therapeutics files $300M mixed securities shelf
06:08 EDT Protara Therapeutics (TARA) files $300M mixed securities shelf
Protara Therapeutics reports Q1 EPS (31c), consensus (37c)
“We’re pleased with the productive discussions we’ve had with the FDA around TARA-002 in LMs,” said Jesse Shefferman, CEO of Protara Therapeutics (TARA). “We intend to submit a BLA for…
Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
The Company intends to submit a Biologics License Application (BLA) for TARA-002 in Lymphatic Malformations (LMs) in 2H 2027 Hosting virtual investor webinar discussing LMs program with key opinion le...
Protara Therapeutics Earnings release: Q1 2026
Protara Therapeutics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Protara Therapeutics Quarterly report: Q1 2026
Protara Therapeutics has published its Q1 2026 quarterly earnings report on May 13, 2026.
Protara Therapeutics Proxy statement: Proxy filing
Protara Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Protara Therapeutics Proxy statement: Proxy filing
Protara Therapeutics filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare ...
Protara Therapeutics Proxy statement: Proxy filing
Protara Therapeutics filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
JPMorgan healthcare analysts hold an analyst/industry conference call
Healthcare Analysts discuss Non-muscle invasive bladder cancer (NMIBC) (relevant companies CG Oncology (CGON) and Protara Therapeutics (TARA) on an Analyst/Industry conference call to be held on April...
Protara Therapeutics reports Q4 EPS (37c), consensus (31c)
“Over the last few months, we reported meaningful clinical and regulatory progress across our portfolio of late-stage programs and are building on this momentum as we advance toward several important…
Protara Therapeutics sees cash runway into 2028
As of December 31, 2025, unrestricted cash and cash equivalents and marketable debt securities totaled $197.9 million, including proceeds from the Company’s $86.3 million public offering in December 2...